Georg Kägi, MD

Quick facts

Phase 2 pipeline

• Capsaicin 1% oral solution · Pain management
  Capsaicin activates TRPV1 receptors, leading to the release of substance P and subsequent pain relief.
• InOrpha Solution

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Georg Kägi, MD portfolio CI brief
• Georg Kägi, MD pipeline updates RSS

Related

• Sector hub: All tracked pharma companies